LianBio Salute del bilancio

Salute finanziaria criteri di controllo 4/6

LianBio ha un patrimonio netto totale di $236.1M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $262.9M e $26.8M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$252.22m
Patrimonio netto	US$236.11m
Totale passività	US$26.79m
Totale attività	US$262.90m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

Feb 23

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Jul 20

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Apr 05

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

Dec 20

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Sep 02

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

May 17

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Mar 03

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Feb 01

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $257.8M ) di LIAN.Y superano le sue passività a breve termine ( $25.6M ).

Passività a lungo termine: Le attività a breve termine di LIAN.Y ( $257.8M ) superano le sue passività a lungo termine ( $1.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: LIAN.Y è esente da debiti.

Riduzione del debito: LIAN.Y non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: Dati insufficienti per determinare se LIAN.Y ha una pista di cassa sufficiente in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se LIAN.Y ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

LianBio Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

LianBio Intends to File Form 25 with SEC

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane